SEARCH:   Advanced

Blood, 15 September 2007, Vol. 110, No. 6, pp. 1756-1761. Prepublished online as a Blood First Edition Paper on May 25, 2007; DOI 10.1182/blood-2006-11-050526. This Article Full Text Full Text (PDF) Supplemental Appendix All Versions of this Article: blood-2006-11-050526v1 110/6/1756    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Teramura, M. Articles by Mizoguchi, H. Search for Related Content PubMed PubMed Citation Articles by Teramura, M. Articles by Mizoguchi, H. Related Collections Hematopoiesis and Stem Cells Immunobiology Red Cells Immunotherapy Clinical Trials and Observations Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  CLINICAL TRIALS AND OBSERVATIONS Treatment of severe aplastic anemia with antithymocyte globulin and cyclosporin A with or without G-CSF in adults: a multicenter randomized study in Japan Masanao Teramura1, Akiro Kimura2, Satsuki Iwase3, Yuji Yonemura4, Shinji Nakao5, Akio Urabe6, Mitsuhiro Omine7, and Hideaki Mizoguchi1 1 Department of Hematology, Tokyo Women's Medical University, Tokyo; 2 Department of Hematology and Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima; 3 Department of Hematology/Oncology, Aoto Hospital, Tokyo; 4 Blood Transfusion Service, Kumamoto University School of Medicine, Kumamoto; 5 Cellular Transplantation Biology, Division of Cancer Medicine, Kanazawa University Graduate School of Medical Science, Kanazawa; 6 Division of Hematology, Nippon Telegraph and Telephone (NTT) Kanto Medical Center, Tokyo; 7 Division of Hematology, Internal Medicine, Showa University Fujigaoka Hospital, Yokohama, Japan We report the results of a randomized study to elucidate whether addition of granulocyte colony-stimulating factor (G-CSF) to immunosuppressive therapy is valuable for the treatment of severe aplastic anemia (SAA) in adults. A total of 101 previously untreated patients (median age, 54 years; range, 19 to 75 years) were randomized to receive antithymocyte globulin (ATG) and cyclosporin A (CyA) (G-CSF– group) or ATG, CyA, and G-CSF (G-CSF+ group). In the G-CSF+ group, the hematologic response rate at 6 months was higher (77% vs 57%; P = .03) than in the G-CSF– group. No differences were observed between the groups in terms of the incidence of infections and febrile episodes. There were no differences between the G-CSF– group and the G-CSF+ group in terms of survival (88% vs 94% at 4 years), and the development of myelodysplastic syndrome (MDS)/acute leukemia (AL) (1 patient vs 2 patients). However, the relapse rate was lower in the G-CSF+ group compared with the G-CSF– group (42% vs 15% at 4 years; P = .01). Further follow-up is required to elucidate the role of G-CSF in immunosuppressive therapy for adult SAA. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: Treatment of Aplastic Anemia Journal Watch Oncology and Hematology, October 16, 2007; 2007(1016): 5 - 5. [Full Text] A. Bacigalupo Aplastic Anemia: Pathogenesis and Treatment Hematology, January 1, 2007; 2007(1): 23 - 28. [Abstract] [Full Text] [PDF]

	Copyright © 2007 by American Society of Hematology         Online ISSN: 1528-0020